Prof. Tarec C. El-Galaly
Professor of Hematology at Aalborg University Hospital, Denmark
Tarec C. El-Galaly is a Professor of Hematology at Aalborg University Hospital.
His main clinical focus is lymphoid malignancies, in particular B-cell malignancies.
His research focus is on epidemiology and outcomes research, especially in the area of prognosis, treatment outcomes, and survivorship.
He has authored over 120 peer reviewed papers, many of which have been published in high impact journals.
Dr. Toby Eyre
Consultant Haematologist at Oxford University Hospitals NHS Foundation Trust, United Kingdom
Dr Toby Eyre is a consultant haematologist at Oxford University Hospitals NHS Foundation Trust specialising in the management of lymphoid malignancies. He is an expert in the management of patients with lymphoma and patients with chronic lymphocytic leukaemia.
He has completed an MD Doctorate Thesis in early phase trials and biomarker studies in aggressive lymphoid disease in 2017. He completed his haematology training in the Oxford Deanery between 2010 and 2017. He is an investigator on a number of national UK lymphoma and chronic lymphocytic leukaemia trials and has published over 125 peer-review articles on areas of lymphoma and CLL and has presented regularly at national and international conferences.
He is a core member of the low-grade lymphoma and elderly high-grade lymphoma NCRI clinical studies group and a member of the BSCH guideline writing groups for various lymphoma subtypes. He is a member of the BSH Haemato-Oncology Task Force and a CLL Forum executive committee.
He also has a strong interest in teaching and training and has completed a post-graduate Diploma in Medical Education. He is the current BSH-NIHR Researcher of the year in 2021 and an Associate Editor at the British Journal of Haematology.
Dr. Ádám Jóna
Assistant Professor - Department of Hematology, University of Debrecen, Hungary
Ádám Jóna, (MD, PhD) is an Assistant Professor at the Department of Hematology at the University of Debrecen, Hungary. He has previously been awarded Hungarian Society of Hematology and Transfusion (Research grant), New National Excellence Program (Pre- Doctorate Scholarship) and “Clinical publication of the year” (Late pulmonary complications of treating Hodgkin lymphoma: bleomycin induced toxicity. (Expert Opin Drug Saf. 2014).
Ádám Jóna previously completed ESMO Clinical Unit Visit Fellowship (Program director: Prof. Anna Sureda) at Institut Català d'Oncologia – Hospital Duran i Reynals,
Hematopoietic Stem Cell Transplant Program. He also worked as a Research Aide (Program director: Prof. Anas Younes) at MD Anderson Cancer Center, Department of Lymphoma & Myeloma.
Ádám is also Associate Section Editor for European Journal of Hematology.
Dr. Shankara Paneesha
Consultant Haematologist- University Hospitals Birmingham, United Kingdom
Honorary Associate Clinical Professor - University of Birmingham
Dr Shankara Paneesha is a Consultant Haematologist at the University Hospitals Birmingham and Honorary Associate Clinical Professor at the University of Birmingham with a specialist interest in Lymphoma, CLL, Stem Cell Transplantation & CAR-T treatment. He completed specialist training in haematology at the West Midlands Deanery in the UK following initial training at the Royal Free and the Royal Marsden Hospitals in London and was appointed as Consultant Haematologist at the Heart of England NHS Foundation Trust in March 2007.
Dr Paneesha worked as a researcher in myeloma and venous thrombosis at Warwick University and has vast experience in the treatment of haematological malignancies, including leukaemia, lymphoma and myeloma, investigation of thrombosis risk factors, and inherited thrombophilia and stem cell transplantation. Dr Paneesha is currently involved in many trials in haemato-oncology, either as Principal Investigator or as Co-Investigator. Dr Paneesha is the Haematology MDT lead since 2012 and the current West Midlands Haematology Advisory Group Chair.
Dr. Jessica Okosun
Associate Professor at the Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London
Consultant Haematologist at St Bartholomew’s Hospital
Dr Okosun, MA MB BChir PhD FRCPath, received her medical degree from the University of Cambridge and undertook her haematology specialty training in London. She did her PhD in the lab of Professor Jude Fitzgibbon focused on genomic profiling of follicular lymphoma. She has clinical and research expertise in the area of lymphomas and leads a translational research group in non-Hodgkin’s lymphoma.
Dr Okosun’s research has been recognised through the Royal College of Pathologist’s Specialty Research Medal and the EHA-ASH Translational Research Training in Haematology (TRTH) Award. Dr Okosun is the translational science lead on a number of UK lymphoma clinical trials. She serves as a member of the UK NCRI Low and High Grade Lymphoma, Brain Lymphoma and Lymphoma Science subgroups. She has additional roles as Chair of the Barts Cancer Centre’s Patient and Public Involvement Research Advisory Group, Member of the Research Committee of the European Haematology Association (EHA), Member of the International Advisory Board for Lancet Haematology, serves on the editorial board of Blood Advances and is Associate Editor for eJHaem.
Dr. Anna Sureda
Head of the Clinical Hematology Department, Institut Català d’Oncologia – Hospitalet, Barcelona, Spain
Anna Sureda, (MD, PhD) is the Head of the Clinical Hematology Department of Institut Català d’Oncologia – Hospitalet, Barcelona. She had previously been a Senior Consultant in Hospital de la Santa Creu i Sant Pau, Barcelona (from January 1991 to December 2010) and a Senior Consultant focused in lymphomas and hematopoietic stem cell transplantation (HSCT) at Addenbrookes–Cambridge University Hospital, UK (December 2010 – December 2012).
Anna Sureda has focused her career on clinical investigations into the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and multiple myeloma patients evaluating novel therapies such as immunotherapy combined with stem-cell transplantation.
Anna Sureda was appointed Chairperson of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT) from March 2004 to March 2010 and Secretary of the same organization from March 2010 to March 2016. She was elected co-chair of the Lymphoma Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR) and has served the organization in this position from February 2015 to February 2019. She was subsequently appointed as member of a large non-US Transplant Center in the Advisory Committee of the CIBMTR (from February 2019). Anna Sureda is President of the Spanish Society of Hematopoietic Stem Cell Transplantation and Cellular Therapy (GETH-TC) and, from March 2022, President of the EBMT.
Anna Sureda is regular reviewer of several peer reviewed journals (Blood, Annals of Oncology, Bone Marrow Transplantation, The Hematology Journal, The European Journal of Hematology & Annals of Hematology) and has co-authored more than 400 manuscripts.